Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.
BACKGROUND
Serological examination of Epstein-Barr virus (EBV) antibodies has been performed for screening nasopharyngeal carcinoma (NPC) and other EBV-associated diseases.


METHODS
By using xMAP technology, we examined immunoglobulin (Ig) A antibodies against Epstein-Barr virus (EBV) VCA-gp125, p18 and IgA/IgG against EA-D, EBNA1 and gp78 in populations with distinct diseases, or with different genetic or geographic background. Sera from Cantonese NPC patients (n = 547) and healthy controls (n = 542), 90 members of high-risk NPC families and 52 non-endemic healthy individuals were tested. Thirty-five of NPC patients were recruited to observe the kinetics of EBV antibody levels during and after treatment. Patients with other EBV-associated diseases were collected, including 16 with infectious mononucleosis, 28 with nasal NK/T cell lymphoma and 14 with Hodgkin's disease.


RESULTS
Both the sensitivity and specificity of each marker for NPC diagnosis ranged 61-84%, but if combined, they could reach to 84.5% and 92.4%, respectively. Almost half of NPC patients displayed decreased EBV immunoactivities shortly after therapy and tumor recurrence was accompanied with high EBV antibody reactivates. Neither the unaffected members from high-risk NPC families nor non-endemic healthy population showed statistically different EBV antibody levels compared with endemic controls. Moreover, elevated levels of specific antibodies were observed in other EBV-associated diseases, but all were lower than those in NPC.


CONCLUSIONS
Combined EBV serological biomarkers could improve the diagnostic values for NPC. Diverse EBV serological spectrums presented in populations with different EBV-associated diseases, but NPC patients have the highest EBV activity.
Gu
Ai-Di
AD
State Key Laboratory of Oncology in Southern China, Guangzhou, PR China. topgad@yahoo.com
Lu
Li-Xia
LX
Xie
Yan-Bo
YB
Chen
Li-Zhen
LZ
Feng
Qi-Sheng
QS
Kang
Tiebang
T
Jia
Wei-Hua
WH
Zeng
Yi-Xin
YX
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D044466:Asian People; D015415:Biomarkers / Q000378:metabolism*; D002648:Child; D002681:China; D020031:Epstein-Barr Virus Infections / Q000097:blood / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis* / Q000276:immunology; D010455:Peptides / Q000235:genetics / Q000378:metabolism; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014764:Viral Proteins / Q000276:immunology
D000914:Antibodies, Viral; D015415:Biomarkers; D007070:Immunoglobulin A; D010455:Peptides; D014764:Viral Proteins
J Med Virol. 1995 Jan;45(1):71-7
7714494
N Engl J Med. 2004 Jun 10;350(24):2461-70
15190138
N Engl J Med. 1989 Mar 16;320(11):689-95
2537928
Methods. 2006 Apr;38(4):317-23
16481199
J Infect Dis. 2007 Feb 15;195(4):483-92
17230407
Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):363-8
9149897
Clin Vaccine Immunol. 2008 Nov;15(11):1684-8
18768669
Crit Rev Oncol Hematol. 2002 Dec;44(3):227-38
12467963
Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1145-53
11700262
Br J Cancer. 1994 Mar;69(3):508-14
8123482
J Infect Dis. 2004 Jul 1;190(1):53-62
15195243
Cancer. 2001 Oct 1;92(7):1872-80
11745260
Int J Cancer. 1990 Jun 15;45(6):1061-4
1693600
Front Biosci. 2006 Sep 01;11:2672-713
16720343
J Clin Microbiol. 2006 Apr;44(4):1459-67
16597877
Int J Cancer. 2004 Aug 10;111(1):117-23
15185352
Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):461-73
11313005
Am J Pathol. 1996 Oct;149(4):1111-8
8863660
Eur J Cancer. 2001 Jul;37(10):1209-16
11423253
J Clin Oncol. 1987 Oct;5(10):1673-89
2821199
J Med Virol. 2005 Apr;75(4):593-602
15714486
Cancer Res. 2004 Mar 15;64(6):1972-4
15026332
Acta Crystallogr D Biol Crystallogr. 2006 Oct;62(Pt 10):1276-85
17001105
Int J Cancer. 1988 Aug 15;42(2):176-81
2841245
Ai Zheng. 2006 Feb;25(2):250-6
16480597
N Engl J Med. 1968 Nov 21;279(21):1121-7
4879667
J Infect Dis. 2004 Jun 15;189(12):2271-81
15181575
Semin Cancer Biol. 2002 Dec;12(6):421-9
12450728
J Gen Virol. 2008 May;89(Pt 5):1152-1158
18420792
Int J Cancer. 1990 Jun 15;45(6):1033-9
2351484
J Clin Microbiol. 2001 Sep;39(9):3164-70
11526145
Br J Cancer. 2007 Feb 26;96(4):623-30
17285127
Environ Health Perspect. 1995 Nov;103 Suppl 8:259-61
8741795
J Med Virol. 2007 Dec;79(12):1877-81
17935169
Nat Genet. 2002 Aug;31(4):395-9
12118254
Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101
5242134
Hematology Am Soc Hematol Educ Program. 2007;:204-9
18024631
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):900-5
15826929
Int J Cancer. 1976 Jan 15;17(1):1-7
175020
Cancer Res. 2000 May 1;60(9):2351-5
10811107
Int J Cancer. 2006 Feb 1;118(3):780-4
16106400
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5
8090780
N Engl J Med. 2001 Dec 27;345(26):1877-82
11756578
Cancer. 1994 Nov 1;74(9):2414-24
7922994
N Engl J Med. 1989 Oct 19;321(16):1080-5
2552313
Hematology Am Soc Hematol Educ Program. 2007;:277-84
18024641
Int J Hematol. 2008 Mar;87(2):110-117
18256789